57.5% achieved remission by week 10*
Clinically meaningful
Reductions in depressive symptoms
Flow FL-100 has demonstrated clinically meaningful reductions in depressive symptoms across the largest controlled trial1 of its kind and real-world clinical practice2, including outcomes from more than 55,000 patients treated in routine care settings.
Potential amplification when used as an adjunct†1
Results at 10 weeks from a multisite, double-blind, placebo-controlled randomised superiority trial demonstrate that Flow FL-100 is effective when used both as a standalone treatment and as an adjunct to antidepressant therapy.
Remission rates when used as an adjunct and standalone at Week 10†1
Response beyond 10 weeks
Follow-up data indicates that many patients who responded early to Flow FL-100 maintained their clinical improvement at Week 20.
Importantly, a subset of patients who had not achieved response by Week 10 experienced delayed improvements with continued treatment. These findings suggest that benefits may continue to emerge beyond the initial treatment period, highlighting the value of ongoing monitoring and structured treatment.
Evidence beyond the trial setting
In addition to controlled trial data, Flow FL-100 has been used in routine clinical practice across the UK and EU2.
Real-world outcomes from tens of thousands of patients provide further insight into adherence, durability of response, and clinical utility outside of research settings.
Users to date
Countries
Stimulations completed
Addressing risk in real-world clinical settings‡
In a real-world crisis care evaluation3, Flow FL-100 use was associated with up to a 75% reduction in reported suicidal ideation and avoided psychiatric hospital admissions, suggesting potential value as a supportive intervention for patients with acute depressive symptoms.
Change in distribution of Depression Severity after 3 weeks3‡
Depression-related sleep symptoms in real-world use
In a retrospective analysis of over 6,000 patients treated with Flow FL-100 for depression, adherent patients showed notable improvements in insomnia, a common symptom of depression, with remission observed in 36% after 1 week and 63% by 10 weeks4.
Sleep quality remission rates among patients adherent to the tDCS protocol4